(NYSE: ZTS) Zoetis's forecast annual revenue growth rate of 3.83% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Zoetis's revenue in 2026 is $9,517,000,000.On average, 21 Wall Street analysts forecast ZTS's revenue for 2026 to be $4,059,095,442,446, with the lowest ZTS revenue forecast at $3,866,946,467,516, and the highest ZTS revenue forecast at $4,300,831,249,616. On average, 21 Wall Street analysts forecast ZTS's revenue for 2027 to be $4,215,707,187,604, with the lowest ZTS revenue forecast at $3,988,020,982,902, and the highest ZTS revenue forecast at $4,556,616,659,254.
In 2028, ZTS is forecast to generate $4,409,509,056,942 in revenue, with the lowest revenue forecast at $4,100,004,579,044 and the highest revenue forecast at $4,819,013,646,524.